Literature DB >> 28609659

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.

Xiaoju Wang, Yuanyuan Qiao, Irfan A Asangani, Bushra Ateeq, Anton Poliakov, Marcin Cieślik, Sethuramasundaram Pitchiaya, Balabhadrapatruni V S K Chakravarthi, Xuhong Cao, Xiaojun Jing, Cynthia X Wang, Ingrid J Apel, Rui Wang, Jean Ching-Yi Tien, Kristin M Juckette, Wei Yan, Hui Jiang, Shaomeng Wang, Sooryanarayana Varambally, Arul M Chinnaiyan.   

Abstract

Entities:  

Year:  2017        PMID: 28609659     DOI: 10.1016/j.ccell.2017.05.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  9 in total

1.  Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.

Authors:  Longjiang Shao; Nermin Kahraman; Ge Yan; Jianghua Wang; Bulent Ozpolat; Michael Ittmann
Journal:  Prostate       Date:  2019-10-15       Impact factor: 4.104

Review 2.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

Review 3.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

Review 4.  ETS factors in prostate cancer.

Authors:  Cheng Qian; Dan Li; Yu Chen
Journal:  Cancer Lett       Date:  2022-01-14       Impact factor: 8.679

5.  Fusion Genes in Prostate Cancer: A Comparison in Men of African and European Descent.

Authors:  Rebecca Morgan; Dulcie Keeley; E Starr Hazard; Emma H Allott; Bethany Wolf; Stephen J Savage; Chanita Hughes Halbert; Sebastiano Gattoni-Celli; Gary Hardiman
Journal:  Biology (Basel)       Date:  2022-04-20

6.  An inhibitor of endothelial ETS transcription factors promotes physiologic and therapeutic vessel regression.

Authors:  Christopher M Schafer; Jami M Gurley; Katarzyna Kurylowicz; Prisca K Lin; Wen Chen; Michael H Elliott; George E Davis; Faizah Bhatti; Courtney T Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-05       Impact factor: 11.205

Review 7.  Chimeric RNAs and their implications in cancer.

Authors:  Zi Li; Fujun Qin; Hui Li
Journal:  Curr Opin Genet Dev       Date:  2017-11-05       Impact factor: 5.578

8.  Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond

Authors:  Simon Linder; Henk G van der Poel; Andries M Bergman; Wilbert Zwart; Stefan Prekovic
Journal:  Endocr Relat Cancer       Date:  2018-10-31       Impact factor: 5.678

9.  Molecular Profiling of Atypical Tenosynovial Giant Cell Tumors Reveals Novel Non-CSF1 Fusions.

Authors:  Theodore Vougiouklakis; Guomiao Shen; Xiaojun Feng; Syed T Hoda; George Jour
Journal:  Cancers (Basel)       Date:  2019-12-31       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.